...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy
【24h】

Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy

机译：使用漫射光谱法预测对乳腺癌新辅助化疗的反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diffuse optical spectroscopy (DOS) and imaging are emerging diagnostic techniques that quantitatively measure the concentration of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctO_2Hb), water(ctH_2O), and lipid in cm-thick tissues. In early-stage clinical studies, diffuse optical imaging and DOS have been used to characterize breast tumor biochemical composition and monitor therapeutic response in stage Ⅱ/Ⅲ neoadjuvant chemotherapy patients. We investigated whether DOS measurements obtained before and 1 week into a 3-month adriamycin/cytoxan neoadjuvant chemotherapy regimen can predict final, postsurgical pathological response. Baseline DOS measurements of 11 patients before therapy revealed significant increases in tumor ctHHb, ctO_2Hb, ctH_2O, and spectral scattering slope, and decreases in bulk lipids, relative to normal breast tissue. Tumor concentrations of ctHHb, ctO_2Hb, and ctH_2O dropped 27 ± 15%, 33 ± 7%, and 11 ± 15%, respectively, within 1 week (6.5 ±1.4 days) of the first treatment for pathology-confirmed responders (n = 6), whereas nonre-sponders (n = 5) and normal side controls showed no significant changes in these parameters. The best single predictor of therapeutic response 1 week posttreatment was ctHHb (83% sensitivity, 100% specificity), while discrimination analysis based on combined ctHHb and ctH_2O changes classified responders vs nonresponders with 100% sensitivity and specificity. In addition, the pretreatment tumor-to-normal ctO_2Hb ratio was significantly higher in responders (2.82 ± 0.44) vs. nonresponders (1.82 ± 0.49). These results highlight DOS sensitivity to tumor cellular metabolism and biochemical composition and demonstrate its potential for predicting and monitoring an individual's response to treatment.
机译：漫射光谱法（DOS）和成像技术是新兴的诊断技术，可定量测量厘米厚组织中的脱氧血红蛋白（ctHHb），氧合血红蛋白（ctO_2Hb），水（ctH_2O）和脂质的浓度。在早期临床研究中，漫射光学成像和DOS被用于表征乳腺肿瘤的生化成分并监测Ⅱ/Ⅲ期新辅助化疗患者的治疗反应。我们调查了在3个月的阿霉素/ cytoxan新辅助化疗方案之前和1周内获得的DOS测量是否可以预测最终的术后病理反应。治疗前对11位患者进行的基线DOS测量显示，相对于正常乳腺组织，肿瘤ctHHb，ctO_2Hb，ctH_2O和光谱散射斜率显着增加，而体脂减少。对于经病理证实的应答者，首次治疗后1周（6.5±1.4天）内，ctHHb，ctO_2Hb和ctH_2O的肿瘤浓度分别下降27±15％，33±7％和11±15％（n = 6） ），而无反应者（n = 5）和正常的旁侧对照显示这些参数没有明显变化。治疗后1周的治疗反应的最佳单一预测指标是ctHHb（83％敏感性，100％特异性），而基于ctHHb和ctH_2O的组合进行的辨别分析则以100％敏感性和特异性将反应者与非反应者进行了分类。此外，治疗前肿瘤与正常人的ctO_2Hb比率在应答者（2.82±0.44）中显着高于未应答者（1.82±0.49）。这些结果突出了DOS对肿瘤细胞代谢和生化成分的敏感性，并证明了其在预测和监测个体对治疗反应方面的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号